Medica Coverage Policy

<table>
<thead>
<tr>
<th>Policy Name:</th>
<th>Fecal Calprotectin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effective Date:</td>
<td>5/1/2017</td>
</tr>
</tbody>
</table>

Important Information – Please Read Before Using This Policy

These services may or may not be covered by all Medica plans. Please refer to the member’s plan document for specific coverage information. If there is a difference between this general information and the member’s plan document, the member’s plan document will be used to determine coverage. With respect to Medicare, Medicaid and MinnesotaCare members, this policy will apply unless these programs require different coverage. Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Medica coverage policy may call the Medica Provider Service Center toll-free at 1-800-458-5512.

Medica coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care and treatment.

Coverage Policy
Fecal calprotectin testing is investigative and therefore NOT COVERED.

Description
Fecal calprotectin testing is a laboratory test that measures the amount of calprotectin present in stool. Calprotectin is a zinc and calcium binding protein released by immune system cells that is thought to trigger and maintain intestinal inflammation in inflammatory bowel disease (IBD). Therefore, it has been proposed as a noninvasive method to differentiate between inflammatory and noninflammatory gastrointestinal conditions, monitor response to therapy and predict recurrence of IBD. Fecal calprotectin is also under investigation as a marker in colorectal cancer, transplant rejection, and a number of other gastrointestinal conditions.

FDA Approval
On April 26, 2006, PhiCal™ Fecal Calprotectin Immunoassay (Calpro AS, Genova Diagnostics, Asheville, NC) was granted U.S. Food and Drug Administration (FDA) 510(k) clearance as an in vitro diagnostic. Since that time, several other test kits have received clearance. In addition, in 2006 the FDA published a guidance document for industry specific to fecal calprotectin immunological test systems, which was last updated in 2015.

Prior Authorization
Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.
Coding Considerations
Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

CPT Codes
83993 – Calprotectin, fecal

Original Effective Date: 5/1/2011
Re-Review Date(s): 2/19/2014
2/15/2017